SCHEMBL1765602

SCHEMBL1765602

CC(C)(C)c1ccc(O)c(-c2ccccc2O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
TDP1 Q9NUW8 2/20 0.57
HPGD P15428 2/20 0.57
HSD17B10 Q99714 2/20 0.57
ALOX15 P16050 1/20 0.57
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
PLA2G1B P04054 1/20 0.53
NFKB1 P19838 1/20 0.53
CASP3 P42574 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
SENP6 Q9GZR1 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ATG4B Q9Y4P1 1/20 0.53
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
MAPT P10636 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7943115 0.90 ALDH1A1 (0.59) ALDH1A1TDP1HPGDHSD17B10ALOX15
SCHEMBL29785519 0.89 ALDH1A1 (0.70) ALDH1A1TDP1HPGDHSD17B10ALOX15
SCHEMBL6240718 0.89 ALDH1A1 (0.70) ALDH1A1TDP1HPGDHSD17B10ALOX15
SCHEMBL30504387 0.87 KMT2A (0.52) ALDH1A1TDP1HPGDHSD17B10ALOX15
SCHEMBL12293443 0.87 HPGD (0.52) ALDH1A1TDP1HPGDHSD17B10ALOX15
SCHEMBL23861345 0.86 ESR1 (0.59) ALDH1A1TDP1HPGDHSD17B10ALOX15
SCHEMBL12293438 0.85 ALDH1A1 (0.50) ALDH1A1TDP1HPGDHSD17B10ALOX15
SCHEMBL12293445 0.85 ALDH1A1 (0.50) ALDH1A1TDP1HPGDHSD17B10ALOX15
SCHEMBL23861494 0.83 ESR1 (0.66) ALDH1A1TDP1HPGDHSD17B10ALOX15
SCHEMBL17500131 0.83 MEN1 (0.50) ALDH1A1TDP1HPGDHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065804-A1 ELECTRODEPOSITED METALLIC FINISHES INCLUDING ANTIMICROBIAL AGENTS PAVCO INC. (US) 2011-03-17 US claimed
WO-2009120784-A2 ELECTRODEPOSITED METALLIC FINISHES INCLUDING ANTIMICROBIAL AGENTS PAVCO INC. (US) 2009-10-01 WO claimed
WO-2002050002-A1 NON-HALOGENATED PHENYL SUBSTITUTED PHENOLS, ANTIMICROBIAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME WARNER-LAMBERT COMPANY LLC (US) 2002-06-27 WO claimed
US-20190257049-A1 Methods and Apparatus for Stabilization of Surfaces Polylast Systems, LLC 2019-08-22 US disclosed
US-10309070-B2 Methods and apparatus for stabilization of surfaces Polylast Systems, LLC (US) 2019-06-04 US disclosed
US-9982143-B2 Methods and apparatus for stabilization of surfaces Polylast Systems, LLC (US) 2018-05-29 US disclosed
US-20170002533-A1 Methods and Apparatus for Stabilization of Surfaces KING COAST INC. 2017-01-05 US disclosed
US-20160333192-A1 Methods and Apparatus for Stabilization of Surfaces KING COAST INC. 2016-11-17 US disclosed
US-8609892-B2 Glucagon receptor antagonists, preparation and therapeutic uses ELI LILLY AND COMPANY (US) 2013-12-17 US disclosed
US-20110124648-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2011-05-26 US disclosed
US-20110065804-A1 ELECTRODEPOSITED METALLIC FINISHES INCLUDING ANTIMICROBIAL AGENTS PAVCO INC. (US) 2011-03-17 US disclosed
EP-1758853-B1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES LILLY CO ELI (US) 2010-01-20 EP disclosed
WO-2009120784-A2 ELECTRODEPOSITED METALLIC FINISHES INCLUDING ANTIMICROBIAL AGENTS PAVCO INC. (US) 2009-10-01 WO disclosed
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses ELI LILLY AND COMPANY (US) 2007-10-25 US disclosed
US-7211700-B2 Non-halogenated phenyl substituted phenols, antimicrobial compositions containing the same, and methods of using the same MCNEIL-PPC, INC. (US) 2007-05-01 US disclosed
EP-1758853-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-03-07 EP disclosed
WO-2005123668-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2005-12-29 WO disclosed
US-20050239903-A1 Non-halogenated phenyl substituted phenols, antimicrobial compositions containing the same, and methods of using the same MCNEIL-PPC, INC 2005-10-27 US disclosed
US-20030207945-A1 Non-halogenated phenyl substituted phenols, antimicrobial compositions containing the same, and methods of using the same HARPER DAVID SCOTT (US) 2003-11-06 US disclosed
US-20020119106-A1 Non-halogenated phenyl substituted phenols, antimicrobial compositions containing the same, and methods of using the same HARPER DAVID SCOTT (US) 2002-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207945-A1 Non-halogenated phenyl substituted phenols, antimicrobial compositions containing the same, and methods of using the same TYR, CLPP, PTPN1 ALDH1A1 3007/4885TDP1 3314/4885HPGD 2481/4885
US-20110124648-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES GLP1R, GCGR, GIPR ALDH1A1 3337/4885TDP1 4706/4885HPGD 1855/4885
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses GLP1R, GCGR, GIPR ALDH1A1 3337/4885TDP1 4706/4885HPGD 1855/4885
US-20050239903-A1 Non-halogenated phenyl substituted phenols, antimicrobial compositions containing the same, and methods of using the same TYR, CLPP, PTPN1 ALDH1A1 3007/4885TDP1 3314/4885HPGD 2481/4885
US-20020119106-A1 Non-halogenated phenyl substituted phenols, antimicrobial compositions containing the same, and methods of using the same TYR, CLPP, PTPN1 ALDH1A1 3007/4885TDP1 3314/4885HPGD 2481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.